SABCS 2021

Benefit only related to chemotherapy?!

Genomic signatures of DCIS

Metformin shows no efficacy for most cancer patients

Metformin is not an anti-cancer drug

Hypothesis-generating study in the HER2-enriched…

Critical consideration of the study data is necessary

The next standard for TNBC?!

Solved and unsolved controversies of early breast…

Leading the way for other ct-DNA trials

The risk-adapted decision for or against AI has to be…

Negative results with hope for translational projects

Molecular-guided treatment is of value in combination…

Re-evaluation confirms old data

La metformina non può essere considerata un farmaco…

E’ solo effetto della chemioterapia?

Genomisch gesteuererte Therapie sinnvoll in Kombi mit…

Hypothesen-generierende Studie beim HER2-enriched…

"Signatures Genomiche " nel carcinoma duttale in situ

Kritische Betrachtung der Studiendaten notwendig

Muss die risiko-adaptierte Entscheidungsfindung bei AI…

Negative Ergebnisse, aber Hoffnung für translationale…

KEYNOTE-522 confirms ICI benefit in the neoadjuvant…

RxPONDER: Benefit only for pre-menopausal patients?…

MOLECULAR DIAGNOSTICS EBC: ctDNA for early detection of…

HR+ EBC: What about PALLAS/PENELOPE-B? What is the…

TNBC EBC: What is the new neoadjuvant standard…

Amazing period for patients with refractory metastatic…

Very good news for endocrine resistant metastatic…

Immuntherapy for high tumor mutation burden in…

Pioneering study of personalized medicine in advanced…

Elacestrant - less than we expected

Effectiveness depending on PDL1 status

Oral SERDs are efficient, but show high progression…

Samuraciclib - new targeted therapy for luminal breast…

3 updates - 3 new standards of care

T-Dxd is also active in patients with brain metastasis

IO + IO without resounding success in the mBC setting

PFS improvement with fulvestrant in patients with…

More good news for TDXd

Oral SERDs for early setting and adjuvant therapy

Reconfirming effect of T-DXd in patients with brain…

Exciting novel therapies for metastatic TNBC

Robust benefit of pembroluzimab in addition to…

TROP2 - new target for improved chemotherapy

Imaging with mass cytometry can provide predictive…

TDXd is very efficient in patients with brain…

Which patients will benefit from Pembro in metastatic…

Final results of the CPS score subgroup analyses show…

Activity of T-Dxd across all Her2-expressing breast…

Best of the year: systemic therapy

Chekpoint inhibition in breast cancer

Promising results for TNBC patients

Patients with BRCA2 don't show PFS benefit with CDK4/6i

Dato-DXd new promising ADC

My highlights of 2021 in metastatic breast cancer

Precision oncology is beneficial in certain mBC…

Dato-Dxd for metastatic TNBC

Pooled analyses shows OS benefit for most subgroups

Dato-DXd – nowy obiecujący koniugat przeciwciała i…

T-Dxd aktywny również w przerzutach do mózgu

Important benefice de l’ajout du pembrolizumab à la…

Amélioration de la survie sans progression par le…

Wegweisende Daten für die personalisierte Medizin beim…

È un grande momento per i pazienti con tumore mammario…

HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil…

Umstellung bei molekularem Progress verlängert PFS

Elacestrant – poniżej oczekiwań

Präzisionsonkologie funktioniert beim mBC

Best of the Year: Systemtherapie

Buone notizie per i tumori mammari endocrino resistenti

Mi retrospectiva del cáncer de mama metastático en 2021

Checkpoint-Inhibition beim Mammakarzinom

IO + IO ohne durchschlagenden Erfolg beim mBC

Neues Target für optimierte Chemotherapie

Oraler Serd wirkt, aber hohe Rate an primärer Resistenz

Resultados finales de los análisis de los subgrupos de…

Werden orale SERDs die Therapie mit Fulvestrant in…

L’imaging mass cytometry può aiutare a predire…

Activité du T-DXd dans les metastases cérébrales

TDXd zeigt große Wirksamkeit bei Hirnmetastasen

Wirksamkeit in Abhängigkeit von PDL1-Stautus

Samuracyklib – nowe leczenie celowane w rakach…

Gepoolte Analyse zeigt OS Vorteil für fast alle…

Résultats prometteurs dans le cancer du sein triple…

MBC HR+: What is the best option after a CDK4/6i…

Integrating patients perspectives in metastatic breast…

MBC TNBC: Molecular tumor characteristics define the…

Treatment options for patients with metastatic TNBC

Therapy of brain metastasis – can T-DXd be the new SoC?

Are SERDs a future therapy for endocrine resistant…

Targeting rare mutations in breast cancer - is this the…